✦ LIBER ✦

Gemcitabine (G) + carboplatin (C) as 2nd line therapy in gynaecologic cancer patients: a phase I/II study of the arbeitsgemeinschaft Gynäkologische Onkologie (AGO) study group

✍ Scribed by J. Quaas; H.J. Lück; W. Schröder; J. Blohmer; R. Kimmig; V. Möbus; J. Pfisterer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel and carboplatin as first-line

✍ J Pfisterer; A du Bois; U Wagner; J Quaas; J.U Blohmer; D Wallwiener; F Hilpert 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Neuroprotection with amifostine in the f

✍ F. Hilpert; A. Stähle; O. Tomé; A. Burges; D. Rossner; K. Späthe; V. Heilmann; B 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 185 KB

A phase II feasibility study of carbopla

✍ Harries, M; Moss, C; Perren, T; Gore, M; Hall, G; Everard, M; A'Hern, R; Gibbens 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 112 KB

A phase I study of IMP321 and gemcitabin

✍ Wang-Gillam, Andrea; Plambeck-Suess, Stacey; Goedegebuure, Peter; Simon, Peter O 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 174 KB

Gemcitabine, epirubicin and docetaxel as

✍ A. Schneeweiss; J. Huober; H.-P. Sinn; D. von Fournier; C. Rudlowski; F. Belderm 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 269 KB

470 Final results of a phase II study of

✍ S. Glück; C. Lobo; G. Lopes; A. Castrellon; J. Hurley; I. Reis; S. Richman; O. S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 49 KB